FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

LORD JONATHAN T MD		 2. Issuer Name and Ticker or Trading Symbol

BIOLASE, INC [ BIOL ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

27042 TOWNE CENTRE DR., SUITE 270		 3. Date of Earliest Transaction (MM/DD/YYYY)

4/28/2022
(Street)

FOOTHILL RANCH, CA 92610
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Series G Preferred Stock 4/28/2022  D  1395.41 (1)(2)D (2)0 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
(1) On March 1, 2022, the Company's board of directors (the "Board") declared a dividend of one one-thousandth of a share of Series G Preferred Stock, par value $0.001 per share ("Preferred Stock"), for each outstanding share of Company Common Stock to stockholders of record at 5:00 p.m. Eastern Time on March 25, 2022 (the "Record Date"), in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on March 25, 2022. As a result, the Reporting Person received 1,395.41 shares of Preferred Stock. The Preferred Stock is not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company.
(2) On April 28, 2022, these shares of Preferred Stock were redeemed automatically in accordance with the certificate of designation for the shares of Preferred Stock. Each share of Preferred Stock was redeemed in consideration for the right to receive an amount equal to $0.01 in cash for each ten whole shares of Preferred Stock, with any remaining shares (of less than 10) receiving no cash.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
LORD JONATHAN T MD
27042 TOWNE CENTRE DR.
SUITE 270
FOOTHILL RANCH, CA 92610		X
Signatures
/s/ Michael C. Carroll, attorney-in-fact for Jonathan T. Lord5/2/2022
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Biolase (NASDAQ:BIOL)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Biolase Charts.
Biolase (NASDAQ:BIOL)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Biolase Charts.